






Review

Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review

Jose Enrique de la Rubia Ortí ^{1,*} , Costanza Moneti ², Pilar Serrano-Ballesteros ³, Gloria Castellano ⁴ , Raquel Bayona-Babiloni ¹, Ana Belén Carriquí-Suárez ^{1,*} , María Motos-Muñoz ^{5,6}, Belén Proaño ¹ , and María Benlloch ¹ 

- ¹ Department of Basic Medical Sciences, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain; raquelbayona03@mail.ucv.es (R.B.-B.); beprool@mail.ucv.es (B.P.); maria.benlloch@ucv.es (M.B.)
 - ² Doctoral School, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain; costanza.moneti@mail.ucv.es
 - ³ Research Department of Sesderma Laboratories, 46001 Valencia, Spain; p.serrano@sesderma.com
 - ⁴ Centro de Investigación Traslacional San Alberto Magno (CITSAM), Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain; gloria.castellano@ucv.es
 - ⁵ Department of Personality Psychology, Treatment and Methodology, Catholic University of Valencia San Vicente Mártir, 46100 Valencia, Spain; maria.motos@ucv.es
 - ⁶ Child Neurorehabilitation Unit, Manises Hospital, 46940 Valencia, Spain
- * Correspondence: joseenrique.delarubi@ucv.es (J.E.d.l.R.O.); a.carriqui@mail.ucv.es (A.B.C.-S.); Tel.: +34-669367704 (J.E.d.l.R.O.); +34-655774322 (A.B.C.-S.)



Citation: de la Rubia Ortí, J.E.; Moneti, C.; Serrano-Ballesteros, P.; Castellano, G.; Bayona-Babiloni, R.; Carriquí-Suárez, A.B.; Motos-Muñoz, M.; Proaño, B.; Benlloch, M. Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review. *Nutrients* **2023**, *15*, 3265. <https://doi.org/10.3390/nu15143265>

Academic Editor: Ruggiero Francavilla

Received: 12 June 2023
Revised: 18 July 2023
Accepted: 21 July 2023
Published: 24 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Autism Spectrum Disorder (ASD) is characterized by varying degrees of difficulty in social interaction and communication. These deficits are often associated with gastrointestinal symptoms, indicating alterations in both intestinal microbiota composition and metabolic activities. The intestinal microbiota influences the function and development of the nervous system. In individuals with ASD, there is an increase in bacterial genera such as *Clostridium*, as well as species involved in the synthesis of branched-chain amino acids (BCAA) like *Prevotella copri*. Conversely, decreased amounts of *Akkermansia muciniphila* and *Bifidobacterium* spp. are observed. Epigallocatechin-3-gallate (EGCG) is one of the polyphenols with the greatest beneficial activity on microbial growth, and its consumption is associated with reduced psychological distress. Therefore, the objective of this review is to analyze how EGCG and its metabolites can improve the microbial dysbiosis present in ASD and its impact on the pathology. The analysis reveals that EGCG inhibits the growth of pathogenic bacteria like *Clostridium perfringens* and *Clostridium difficile*. Moreover, it increases the abundance of *Bifidobacterium* spp. and *Akkermansia* spp. As a result, EGCG demonstrates efficacy in increasing the production of metabolites involved in maintaining epithelial integrity and improving brain function. This identifies EGCG as highly promising for complementary treatment in ASD.

Keywords: Autism Spectrum Disorder (ASD); microbiota; epigallocatechin-3-gallate (EGCG); inflammation; oxidative stress

1. Introduction

Autism Spectrum Disorder (ASD) is a highly heterogeneous and complex disorder characterized by two major groups of core symptoms: (1) persistent deficits in social communication and interaction and (2) restricted and repetitive patterns of behavior, interests, or activities [1–5]. Current epidemiology statistics indicate that the disorder affects approximately 1 in every 160 children worldwide [6].

Characteristic deficits are often associated with a range of gastrointestinal symptoms such as abdominal pain, diarrhea, or constipation [7,8]. Several studies have found that

both the composition of the intestinal microbiota and metabolic activities may be altered in individuals with the disorder ASD [9,10]. Therefore, several authors concur that disruptions in the microbiota and intestinal microbiome, i.e., the collection of microorganisms present in the human gastrointestinal tract and their respective genomes [3,11], could trigger many of the gastrointestinal issues experienced by children with ASD, as well as exacerbate some of the core symptoms of the disorder [12,13].

Microbial colonization begins in infancy via the acquisition of maternal microbiota during vaginal delivery [3]. Subsequently, beneficial microorganisms feed on breast milk, which has a high content of oligosaccharides [14]. Similarly, the composition of the microbiota in the early years may be subject to alterations influenced by the delivery method, hygiene habits, and feeding practices and routines. Among these factors, formula feeding has a particularly significant impact [3].

It has been shown that the intestinal microbiota affects the function and development of the immune, metabolic, and nervous systems. Regarding the immune and metabolic systems, intestinal microbiota and its metabolites impact host physiology by regulating the function of the intestinal barrier, redox and mitochondrial metabolism, and mucosal inflammatory response via the regulation of intestinal lymphocytes that provide resistance against potential pathogens [15–20]. On the other hand, intestinal microbiota can influence neurochemistry, function, gene expression, and the development of the central nervous system (CNS) through the gut–brain axis, which represents a bidirectional link between the cognitive and emotional functions of the CNS and peripheral intestinal function [15,21–23]. It is worth noting that the genus *Bifidobacterium* can metabolize gamma-aminobutyric acid (GABA), *Lactobacillus* spp. can metabolize acetylcholine, *Bacillus* spp. and *Serratia* spp., dopamine, and *Escherichia* spp. and *Saccharomyces* spp., noradrenaline. All these neurotransmitters are essential for the proper functioning of the nervous system as they can enter circulation and directly affect neural processes throughout the body, including the brain [3,24]. Additionally, intestinal proinflammatory cytokines, particularly TNF and IL-6, can have an impact on the brain because they make the blood–brain barrier (BBB) more permeable, allowing peripheral immune cells to enter the brain and stimulating brain cells to produce additional proinflammatory mediators [25,26].

All of this has led to the hypothesis that the development of symptoms related to ASD may be influenced by the disturbance of the gut–brain–microbiota axis caused by changes in the intestinal microbiota.

2. Alterations in the Intestinal Microbiota in ASD

The Firmicutes (40–60%) and Bacteroidetes (20–40%) are the two major phyla of bacteria in the healthy human intestinal flora, followed by Proteobacteria, Actinomycetes, *Clostridium* spp., and Verruciformis [3,27]. However, compared to a healthy population, increased levels of bacterial genera such as *Clostridium*, *Desulfovibrio*, and *Ruminococcus* have been observed [15,28], in ASD, along with species that synthesize BCAA such as *Bacteroides vulgatus* and *Prevotella copri*. On the other hand, lower quantities of *Bacteroides fragilis*, *Akkermansia muciniphila*, *Bifidobacterium* spp., and *Enterococcus* spp. have been found [29,30]. Additionally, the ratio of the *Escherichia/Shigella* genera is altered, as *Shigella* spp. is present at higher levels, while *Escherichia coli* is decreased [31].

It should be noted that, despite the consensus regarding these alterations, it is important to consider that not all studies quantifying the microbiota in ASD analyze the same species or genera, leading to some heterogeneity in the results, and various studies emphasize the relationship between the composition of the human intestinal microbiota and the individual's diet, which can lead to variations in composition depending on the region where the analyses were conducted [32]. In fact, a study in the United States highlighted that children with ASD had lower levels of *Bifidobacterium* spp. and *Prevotella* spp., but higher levels of *Lactobacillus* spp., compared to healthy children [33]. Another study in China described that children with ASD had higher levels of the Actinobacteria and Proteobacteria phyla than the control group [34].

Furthermore, the review conducted by Ho et al. (2020) concluded that although the results of different studies are not entirely consistent [35], some articles indicate that individuals with ASD exhibit a decrease in the percentage of the phylum Bacteroidetes [10,35] or no significant difference [31,36,37] compared to the control group of healthy individuals. This could be due to the fact that within the phylum Bacteroidetes, there are bacteria of the genus *Bacteroides* spp. that are increased, such as *B. vulgatus*, while others are decreased, such as *B. fragilis*, potentially leading to a compensatory effect that results in an unclear profile [30].

The genus *Prevotella* presents a more variable pattern. In the aforementioned review, the authors noted a lower relative abundance of *Prevotella* spp. in children diagnosed with ASD compared to the control group. However, multiple studies indicate an elevated prevalence of *Prevotella* spp. in children with ASD [15,30,31,38], and this variability could be due to dietary factors. Filippo et al. (2010) compared the composition of *Prevotella* spp. in the microbiota of children following European and African diets and observed a significant increase in *Prevotella* spp. In the microbiota of African children, likely due to their consumption of a grain-rich diet [39].

Finally, to establish a correlation between gastrointestinal issues and behavioral problems with the microbiota, the high growth rates of *Clostridium histolyticum*, *Clostridium difficile*, *Clostridium perfringens*, and *Sutterella* spp., the alteration in the *Escherichia/Shigella* genera ratio, and the decreased Bacteroidetes/Firmicutes phylum ratio have been identified as factors associated with gastrointestinal problems. Furthermore, the relative abundance of *Desulfovibrio* spp., *Clostridium* spp., and *Bacteroides vulgatus* has been linked to behavioral disorders [40].

3. Polyphenols as a Therapeutic Alternative to ASD: The Epigallocatechin-3-Gallate (EGCG) Option

ASD lacks a medical cure, and understanding molecular pathogenic mechanisms is crucial for proposing alternative therapies to current medications used for treating autism-related symptoms [41]. Given disruptions in the microbiota, exploring the microbiota-gut-brain axis is essential to modify disease development. Polyphenols, as bioactive dietary compounds, show great promise in this regard. These compounds act in the intestine, reducing inflammation and modulating the microbiota and its metabolites. They also have neuroprotective effects on the brain by crossing the BBB [42].

Polyphenolic antioxidants, capable of targeting the intestine and modulating the intestinal microbiota while reducing intestinal inflammation, have been shown to influence memory, cognition, mood, and behavior, thereby contributing to the prevention and treatment of various brain disorders [25]. Polyphenols have garnered attention for their ability to stimulate certain gut bacteria involved in phenolic compound utilization and metabolism, making them a proposed treatment option for neurological disorders [43,44]. Polyphenols are the most ubiquitous phytochemicals in the human diet, with a total daily intake of approximately 1 g [45]. These phenolic compounds, as secondary metabolites in plants, primarily protect them against various aggressions or infections caused by bacteria, insects, or viruses [43,44]. These protective properties in plants are expected to be beneficial for humans as well. Polyphenolic compounds found in green and black tea are the most potent inhibitors of microbial growth.

These compounds include epigallocatechin-3-gallate (EGCG), epicatechin gallate, epigallocatechin, catechin gallate, epicatechin, and catechin [46]. They have shown significant efficacy in inhibiting the growth of pathogens such as *Helicobacter pylori* [47], *Staphylococcus aureus*, *Escherichia coli* O157:H7 [48,49], *Salmonella typhimurium* DT104, *Listeria monocytogenes*, methicillin-resistant *Staphylococcus aureus* [50,51] and *Pseudomonas aeruginosa* [52]. They have also been effective against viruses like HIV and Epstein–Barr [53,54].

Among all the polyphenols, several studies highlighted by Duda-Chodak et al. (2015) emphasize the significant role of EGCG [55]. EGCG is the primary catechin in green tea,

but it is also found in lower concentrations in certain plant-based foods, such as apples, peaches, kiwis, blackberries, pears, and nuts like pistachios, hazelnuts, and walnuts [56].

Hence, considering the advantageous effects observed on the microbiota from polyphenols, including EGCG, a comprehensive mini-review was proposed. This review was based on a thorough scientific search of published studies in PubMed, without any limitations on publication date. The objective was to examine the potential advantages that EGCG might offer to individuals with ASD. The search was from January to April 2023 and utilized MeSH descriptors like “epigallocatechin gallate”, “autism spectrum disorder”, “metabolism”, “microbiota”, and “fatty acids” combined using the boolean operator “AND”.

3.1. Possible Role of EGCG in the Intestinal Microbiota of Patients with ASD

To date, there is a lack of published studies that have used EGCG in ASD. However, there are cellular and animal studies [57,58] that clearly demonstrate the potential of this antioxidant for the clinical treatment of ASD. Additionally, in recent years, several studies have been published employing other polyphenols that are structurally similar to EGCG, such as luteolin or quercetin, which have achieved evident clinical benefits in the disease [59–62]. Its consumption is linked to reduced psychological distress [63], possibly by inhibiting the growth of specific pathogenic bacteria such as *Clostridium perfringens*, *Clostridium difficile* [64], *Bacteroides ovatus*, and enterobacteria (*Salmonella* spp., *Escherichia coli*, *Yersinia pestis*, *Klebsiella* spp., *Shigella* spp., and *Eggerthella* spp.) [49,65–67]. Furthermore, in the intestinal microbiota, EGCG increases the abundance of *Bifidobacterium* spp., determined via in vitro studies [65] or in *Drosophila* models of Parkinson’s disease [66]. EGCG also increases in vitro bacteria of the *Bacteroides* genus (*Bacteroides uniformis*, *Bacteroides stercoris*, *Bacteroides thetaiotaomicron*, and *Bacteroides cellulosilyticus*) and *Lachnospirillum* spp. [65] in Male C57BL/6N mice *Akkermansia* spp. [67] and in ovariectomized (OVX) mice fed a high-fat diet (HFD) *Prevotella* spp. [68].

A substantial portion of the vital microorganisms in the fecal microbiota of breastfed infants consists of species from the *Bifidobacterium* genus [69]. *Bifidobacterium* spp. has psychobiotic effects that help reduce anxiety, stress, and other depressive behaviors, particularly strains *B. longum* and *B. breve* [70,71]. This bacterial genus is one of the initial colonizers of the newborn’s intestines, and an imbalance in *Bifidobacterium* spp. can affect infant neurodevelopment [71]. Administering EGCG to increase *Bifidobacterium* spp. has been found to enhance the intestinal microbiota, as supported by previous animal studies that showed an elevated abundance of *Bifidobacterium* spp. in response to a diet enriched with EGCG [72].

Bacteria within the *Bacteroides* genus play a crucial role in breaking down complex molecules, particularly carbohydrates, and confer advantages to their hosts by impeding the colonization of potential pathogens in the digestive tract [73,74]. It has been seen that there are bacteria capable of modulating the immune system. For instance, *B. fragilis* has been shown to restore the balance of T-cell populations in mice affected by ASD [75], while *B. uniformis* enhances the production of anti-inflammatory cytokines and improve metabolic and immune dysfunction [65]. Moreover, this genus can improve social behaviors and physiological abnormalities in individuals with ASD [76], indicating that an increase in *Bacteroides* abundance caused by EGCG could enhance the quality of life in patients. Additionally, this polyphenol can reduce *B. ovatus*, the main intestinal commensal responsible for a systemic antibody response in inflammatory bowel disease [77]. These findings suggest that even within the same genus, EGCG may exert different effects on bacterial species.

Prevotella spp. are bacteria that exist in the human microbiota, and are responsible for degrading plant polysaccharides and participating in the synthesis of vitamin B1 [78]. One specific species within the *Prevotella* genus is *Prevotella copri*, which has been linked to enhanced glucose and insulin tolerance. It is commonly found in individuals who consume a diet rich in fiber, indicating a strong association between the effects of this bacterium and dietary habits. Within the *Prevotella* genus, *Prevotella copri* can be found. This species has been associated with improved glucose and insulin tolerance and is commonly found in

individuals who follow a fiber-rich diet, suggesting a strong connection between the effects of this bacterium and dietary patterns [79–82]. Consequently, both the bacteria within the *Prevotella* genus and their metabolic activity are significantly relevant to ASD. On one hand, children with ASD present a higher risk of obesity, which implies insulin resistance [83], and, on the other hand, these children exhibit selective eating patterns, with a notable preference for high amounts of simple carbohydrates and low intake of fiber [84]. This dietary behavior is associated with lower levels of *Prevotella* spp. within the microbiota. Additionally, it is worth noting that individuals with ASD have been reported to have low levels of vitamin B1, which plays a significant role in antioxidant activity [85].

In relation to the *Lachnospirillum* genus, it has been seen to possess anti-inflammatory properties and contribute to the maintenance of intestinal balance by producing butyric acid [86]. This metabolite aids in the elimination of intestinal gases, and its absence is associated with irritable bowel syndrome (IBS) [87]. Therefore, the increase in *Lachnospirillum* spp. mediated by EGCG [56] can be seen as having a positive impact on the microbiota of ASD patients.

EGCG modulates intestinal microbiota and its metabolites, enriching the population of short-chain fatty acid (SCFA)-producing bacteria such as *Akkermansia* spp., resulting in an improvement in the production of acetate, propionate, and butyrate in a sodium dextran sulfate (SDS)-induced colitis mouse model, where levels of these metabolites were significantly reduced [88,89]; this promotes an anti-inflammatory and antioxidant state in the intestine. [88]. *Akkermansia* spp. utilizes intestinal epithelial mucin as a source of energy. By degrading mucin, it releases nutrients such as monosaccharides, amino acids, and SCFAs, which are used by other bacteria in the microbiota, stimulating their metabolic functions [90]. *Akkermansia* spp. is involved in the regulation of glucose metabolism and adipose tissue homeostasis. Therefore, the fact that EGCG increases the levels of *Akkermansia muciniphila* improves intestinal dysbiosis and enhances barrier integrity [67,91–93].

Moreover, among the bacteria reduced by EGCG, Clostridia stand out as a group of Gram-positive bacilli that, when in excess, can lead to infection in the large intestine [28]. Clostridia produce significant compounds such as butyrate or butyric acid, along with other SCFAs generated from the fermentation of dietary fiber. [94]. Butyrate is an essential metabolite in the human colon as it is the preferred energy source for colonic epithelial cells. It contributes to maintaining intestinal barrier functions and has immunomodulatory and anti-inflammatory properties [95]. However, excessively high levels of this metabolite in the intestine promote intestinal permeability, which may allow the passage of toxic substances into the bloodstream, potentially leading to inflammation [94]. Thus, EGCG's inhibitory effect on this bacterial group, as observed in rats and resulting in decreased levels of *Clostridium* spp., balancing their levels, is beneficial [72]. This is particularly relevant for *Clostridium perfringens*, as it significantly impacts disease symptomatology, including gastrointestinal issues. Both the bacterium itself and the gene that produces its toxin (CPB2) have been linked to gastrointestinal complications in ASD and are correlated with disease severity. Moreover, the isolated species from children with ASD show greater antibiotic resistance compared to healthy children [96]. Conversely, the increase in *Clostridium difficile* has a notably negative impact on ASD, and effective treatments against this bacterium using oral vancomycin have shown improvements in behavior and communication [97,98]. Therefore, the reduction of this strain mediated by EGCG could be beneficial for the clinical presentation of children affected by ASD.

EGCG treatment also leads to a decrease in enterobacteria, which are commonly present in the body but can cause infections when their growth is uncontrolled. Certain species have been linked to specific pathologies. In particular, *Salmonella typhi* is responsible for typhoid fever, *Shigella dysenteriae* is the causative agent of bacillary dysentery and causes infantile gastroenteritis, and *Yersinia pestis* causes plague [99].

Lastly, it is important to highlight that specific bacteria increased by EGCG, such as *Lactobacillus acidophilus*, *Bifidobacterium longum*, *Akkermansia muciniphila*, and *Prevotella*

ruminicola, restore the balance of the intestinal microbiota when included to the diet, reducing oxidative stress in the intestine and the brain [100] (Table 1).

Table 1. Main results related to EGCG effects on microbiota populations.

Study	Study Type	Population/Sample Size	Intervention	Results	Ref.
Ankolekar C et al., 2011	Analytical Longitudinal Experimental	Cultures of <i>Helicobacter pylori</i> Lactic acid bacteria strains such as <i>B. longum</i> , <i>L. acidophilus</i> , and <i>L. plantarum</i>	They were exposed to tea preparations with rest times of 2 and 5 min	The 4 types of tea inhibited <i>H. pylori</i>	[47]
Shin JS et al., 2007	Analytical Cross-sectional Experimental	Cultures of bacteria like <i>S. aureus</i> and <i>E. coli</i>	The antibacterial activities of the main phenolic components of <i>Camellia sinensis</i> Green tea extract concentration was 0.0625 mg/mL for <i>S. aureus</i> and 1.0 mg/mL for <i>E. coli</i> O157:H7.	(-)-epicatechin is more toxic against <i>S. aureus</i> and <i>E. coli</i>	[48]
Nakayama M et al., 2012	Analytical Longitudinal Experimental	Different cultures: <i>E. coli</i> O157:H7 producing Stx 1 and Stx 2 <i>S. aureus</i> NBRC 13276		Green tea extract (GTE) inhibits the absorption and secretion of substrates and inhibits enzyme activity in both species	[49]
Bancirova M et al., 2010	Analytical Cross-sectional Experimental	Cultures of standard strains of <i>Enterococcus faecalis</i> 4224, <i>S. aureus</i> 3953 and 4223, <i>P. aeruginosa</i> 3955 and <i>E. coli</i> 3954 and 3988	Tea infusion (2 g/100 mL)	<i>E. faecalis</i> was the most resistant bacterial strain and <i>P. aeruginosa</i> was the least resistant bacterial strain. But the predominant antimicrobial activity of non-fermented tea infusions was not confirmed. EGCG increases the beneficial bacteria <i>Bacteroides</i> , <i>Christensenellaceae</i> , and <i>Bifidobacterium</i> . And inhibited the pathogenic bacteria <i>Fusobacterium varium</i> , <i>Bilophila</i> , and <i>Enterobacteriaceae</i> .	[52]
Liu Z et al., 2020	Analytical Cross-sectional Experimental	Cultures of fecal material from four human volunteers	Treatment with catechin concentration of 0.1 mmol/L during 48 h.		[65]
Trovò L et al., 2020	Analytical Longitudinal Experimental	In vivo study with Cdk15-KO mice N = 5–6	Primary hippocampal neurons were treated daily with EGCG [1 µM, 0.5 µM, 1 µM, and 3 µM] or harmine	Treatment with EGCG efficiently restores defects in the dendritic and synaptic development of Cdk15-KO hippocampal neurons.	[57]
Kumaravel P et al., 2017	Analytical Longitudinal Experimental	In vivo study with Wistar rats N = 6 per group	Rats were treated with EGCG in doses of 1, 2, and 5 mg/kg body weight via oral administration.	EGCG ameliorates and reverses autistic attributes possibly due to its neuroprotective activity.	[58]
Ushiroda C et al., 2019	Analytical Longitudinal Experimental	In vivo study with male C57BL/6 N mice	EGCG at a concentration of 0.32% for 8 weeks	EGCG increases the abundance of <i>Adlercreutzia</i> , <i>Akkermansia</i> , and <i>Allobaculum</i> and a significantly lower abundance of <i>Desulfovibrionaceae</i>	[67]
Qu Y et al., 2022	Analytical Longitudinal Experimental	In vivo study with female C57BL/6 mice (8–13 weeks old)	EGCG [45 mg/kg] was administered for 8 weeks. The mice were then subjected to behavioral and gut microbiota analysis	EGCG effectively increased <i>Prevotella</i> and decreased <i>Bifidobacteriales</i> but had no effect on <i>Alloprevotella</i> or <i>Lactobacillaceae</i>	[68]
Unno T et al., 2014	Analytical Longitudinal Experimental	In vivo study with four-week-old male Wistar rats N= 7 per group	Rats were fed an assigned diet of either a control diet, a 0.3% (w/w) EGCG diet, or a 0.6% (w/w) EGCG diet for 4 weeks	Dietary EGCG affects the growth of certain species of gut microbiota which could be responsible for regulating energy metabolism in the body Oral EGCG suppressed DSS-induced oxidative stress in the intestinal mucosa, improved the barrier function, and regulated the composition and SCFAs production of gut microbiota	[72]
Wu Z et al., 2021	Analytical Longitudinal Experimental	In vivo study with seven- to eight-week-old specific pathogen-free (SPF) female C57BL/6J mice N = 8 per group	Modulated the gut microbial community of mice by the EGCG [50 mg/kg] pre-supplementation		[88]
Wu Z et al., 2020	Analytical Longitudinal Experimental	In vivo study with seven- to eight-week-old specific pathogen-free (SPF) female C57L/6J mice	Tested the effect of oral or rectal administration of EGCG [50 mg/kg]	EGCG enriched <i>Akkermansia</i> , <i>Faecalibaculum</i> , and <i>Bifidobacterium</i> and enhanced acetate, propionate, and butyrate production.	[89]

Table 1. Cont.

Study	Study Type	Population/Sample Size	Intervention	Results	Ref.
Sheng L et al., 2018	Analytical Longitudinal Experimental	In vivo study with specific pathogen-free male C57BL/6 wild-type (WT) mice N = 16	Mice received vehicle (PBS) or EGCG daily [100 mg/d per gram body weight, orally] for 2 mo.	Increased <i>Verrucomicrobiaceae</i> and <i>Akkermansia muciniphila</i> .	[92]
Liu X et al., 2020	Analytical Longitudinal Experimental	In vivo study with C57BL/6J male mice N = 8	C57BL/6J mice fed with HFD were administrated with 210 mg/kg EGCG for 12 weeks.	Enriched the <i>Verrucomicrobia</i> and decreased the <i>Firmicutes</i> and <i>Saccharibacteria</i> .	[93]

3.2. Outlook on the Anti-Inflammatory and Antioxidant Activity of EGCG in Autism: Neuroprotective Role

Immune system dysregulation, inflammation, and increased oxidative stress are significant factors in ASD [101], which is directly linked to dysbiosis. Comorbid inflammatory conditions associated with immune dysregulation closely contribute to the emergence and progression of clinical features in children with ASD [102–104]. Cytokines are small proteins regulating inflammation and neurological development. Increased levels of some of them, particularly, IL-4 or IL-10, have been seen in children with ASD [105]. Notable changes in interferon- α (IFN- α), interleukin-7 (IL-7), IFN- γ -inducible protein-10, and IL-8 are particularly relevant to the disorder's pathogenesis [106].

IL-1 β and IL-10 levels produced by blood monocytes, along with the IL-1 β /IL-10 ratio and miRNA expression, are relevant to innate immunity [107,108]. All these alterations are closely associated with social behavioral impairments and cognitive development in children with ASD [109], which could be due to a brain dysfunction associated with the proper production of growth factors and neurogenesis [110]. In particular, the brain-derived neurotrophic factor (BDNF) plays important roles in the formation, branching, and connectivity of synaptic connections during development [111,112], as well as in synaptic plasticity, as it is involved in learning and memory [113,114].

Oxidative stress is directly linked to intestinal microbiota, particularly in children with ASD [115]. The fermentation of dietary fibers and resistant starch in the gut generates SCFAs [116], with propionate being associated with gastrointestinal issues and neuroinflammation in ASD [117]. Consequently, oxidative stress, closely tied to dysbiosis, plays a crucial role in the neuroinflammatory response and the development of ASD [118–122]. Children with autism exhibit differences in antioxidant capacity and oxidative stress-related metabolites compared to healthy children [123]. The imbalance in glutathione levels and a decreased storage capacity contribute to increased susceptibility to oxidative stress in autistic children [124]. Moreover, increased free radical production, influenced by amyloid precursor proteins (APP), is observed in various human disorders, including autism [125–127].

Polyphenols, particularly EGCG, play a role as antioxidants and promote neurogenesis and plasticity in a Down syndrome mouse model [128], showing potential in alleviating autistic symptoms. Other polyphenols, such as cyanidin-3-glucoside, reduce intestinal inflammation in human intestinal cells, affect inflammatory cascades like nuclear factor kappa B (NF- κ B), activator protein-1 (AP-1), and Janus kinase-signal transducer and activator of transcription (JAK/STAT) [129]. Furthermore, resveratrol in vitro modulates inflammatory markers, including nitric oxide (NO), tumor necrosis factor- α (TNF- α), ionized calcium-binding adapter molecule 1 (Iba1), prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) [130]. Moreover, a study on rat pups with autistic traits found that a polyphenol–probiotic complex reversed autistic behaviors and modulated biochemical changes in IL-6, TNF- α , BDNF, 5-HT, AChE, and the granular layer, which is supported by all this evidence [131].

Therefore, when analyzing the activity of various polyphenols in inflammation and oxidative stress, these molecules have demonstrated high efficacy in regulating APP levels [132]. Its ability to cross the BBB (based on the hBMEC model, which utilizes human-

derived brain endothelial cells), plays a significant role in protecting cortical neurons against oxidative stress-induced cell death. Comparatively, EGCG demonstrated rapid BBB permeation, while cyanidin-3-glucoside (C3G) showed slower permeation, and quercetin did not cross the BBB. This makes EGCG particularly promising as a neuroprotector among various polyphenols [133]. In relation to ASD, IL-8 stands out among the cytokines involved. The administration of oral EGCG reduces its levels via the inhibition of intracellular Ca^{2+} levels and the activation of ERK1/2 and NF-kappaB pathways. This is because it has been seen in the colon that the treatment of TNF- α -stimulated HT29 cells (human colon carcinoma cell lines) with EGCG inhibits IL-8 production by regulating genes in inflammatory pathways, suggesting its potential for preventing or mitigating colonic disorders in autism [134].

Finally, it should be noted that elevated levels of reactive oxygen species (ROS), specifically hydrogen peroxide (H_2O_2) and superoxide (O_2^-), are reported in the intestine of children with ASD as a cause of damage to the epithelial tissue [135–137], and EGCG negatively regulates the inflammatory response in inflamed intestinal epithelial cells, largely via a post-transcriptional regulatory mechanism [138].

3.3. Role of EGCG in the Metabolic Activity Associated with Dysbiosis in ASD

EGCG regulates the production of SCFAs [42], which are the metabolites involved in the bidirectional communication between the gut and the brain. Succinate and butyrate are particularly important and can be altered in individuals with autism due to microbial activity [139]. An imbalanced ratio of succinate production/consumption can cause intestinal disturbances and impact the gut–brain axis [140]. Cheng et al. determined via a review that altered succinate levels have been linked to disrupted calcium homeostasis and dysregulated metabolic functions in autistic individuals [41].

Regarding butyrate, it has been seen that children with ASD have lower levels of fecal butyrate, as well as a decrease in the abundance of taxa producing this metabolite [141]. Butyrate is particularly relevant in ASD as its production mainly derives from the gut microbiome. Butyrate displays potent anti-inflammatory activity that contributes to gut health, regulates intestinal homeostasis, and modulates the expression of neurotransmitter genes [142,143]. Furthermore, it positively modulates the impaired mitochondrial function in ASD, characterized by reduced activity of complex IV in the electron transport chain (ETC) [144], including improvements in oxidative phosphorylation and beta-oxidation. These observations have underscored the significant neuroprotective role of butyrate in children with ASD [145]. In fact, it has recently been seen that maternal treatment with butyrate in the BTBR mouse model of ASD rescues social and partially repetitive behavior deficits in the offspring [146]. Thus, proper butyrate production at adequate levels is crucial, and this depends on the correct development of the gut bacterial community. Oral EGCG delivery on the DSS-induced murine colitis model has been shown to increase both the abundance of *Akkermansia muciniphila* and its butyrate production [88], potentially reversing the adverse effects resulting from altered butyrate levels in ASD. On the other hand, among the altered fecal metabolite profiles in children with ASD (not present in neurotypical children), there is an increase in p-cresol, caprate, and aspartate and a reduction in GABA, nicotinate, glutamine, and thymine [147]. Among all these metabolites, p-cresol is a uremic toxin produced by certain strains of *Clostridium* spp., which has negative biological effects and appears to adversely affect the homeostasis of colonic epithelial cells in children with ASD. When present in excess, p-cresol induces DNA damage in vitro and negatively affects the integrity of colonic epithelial cells [148]. In fact, EGCG may have beneficial effects by reversing the activity of this metabolite. In a recent study, it has been seen that an EGCG-enriched diet reduces plasma and urinary concentrations of p-cresol in mice by suppressing the abundance of Firmicutes at the phylum level and Clostridia at the order level [149].

In conclusion, EGCG has an impact on both the intestinal microbiota and variables directly related to the microbiota such as metabolites, inflammation, and oxidative stress, which could provide benefits for patients with ASD (Figure 1).




Figure 1. EGCG impact in patients with ASD. Alterations in the intestinal microbiota in ASD and its implications on the left; EGCG impact on both the intestinal microbiota and variables directly related to the microbiota such as metabolites, inflammation, and oxidative stress on the right. (↑) means increase and (↓) means decrease.

Another noteworthy aspect is the impact of metabolites generated from the interaction between the polyphenol and the intestinal microbiota. Particularly, in rats, the metabolic pathway of EGCG leads to gallic acid (GA) and epigallocatechin (EGC) [150]. EGC is degraded via colonic bacteria to yield microbial ring-fission metabolites, specifically converting to 5-(3',5'-dihydroxyphenyl)- γ -valerolactone (EGC-M5). Then, the bacteria *Adlercreutzia equolifaciens* MT4s-5 and *Flavonifractor plautii* MT42 are capable of degrading EGC. The bacterium *Adlercreutzia equolifaciens* MT4s-5 catalyzes the conversion of EGC to 1-(3,4,5-trihydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ol (EGC-M1), and subsequently, *Flavonifractor plautii* MT42 converts the propan-2-ol to 5-(3,4,5-trihydroxyphenyl)- γ -valerolactone (EGC-M5) and 4-hydroxy-5-(3,4,5-trihydroxyphenyl)valeric acid (EGC-M4). Similarly, EGC-M5 is produced from 1-(3,5-dihydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ol (EGC-M3), which is formed from EGC via *Adlercreutzia equolifaciens* MT4s-5 in the presence of hydrogen [120]. A large portion of the formed EGC-M5 is absorbed and undergoes glucuronidation in the intestinal mucosa and/or liver to form EGC-M5 glucuronide (EGC-M5-GlcUA), which is distributed to various tissues through the bloodstream and ultimately excreted in urine [151] (Figure 2).

The microbial ring-fission metabolites of EGCG are found in plasma in both free and conjugated forms [151], and in vitro studies have shown that they may reach the brain parenchyma through the BBB, promoting neuritogenesis and potentially exerting a relevant activity against the degenerative processes of neurodegenerative diseases [152].

Specifically, when assessing the penetration capacity of these metabolites through the BBB, it has been seen that GA has higher permeability than EGCG and EGC, possibly due to its smaller molecular size [153]. Moreover, comparing only the ring-fission metabolites derived from EGC, EGC-M5 demonstrated greater permeability than its conjugate EGC-

The diagram illustrates the metabolic pathway of Epigallocatechin gallate (EGCG) mediated by intestinal microbiota:

- EGCG** is converted by *microbiota intestinal* into **GA** (Gallic acid) and **EGC** (Epigallocatechin).
- EGC** is further metabolized by *A. equolifaciens* MT4s-5 into **EGC-M1**.
- EGC** can also be converted by *A. equolifaciens* MT4s-5 / H₂ into **EGC-M3**.
- EGC-M3** is converted by *F. plautii* MT42 into **EGC-M4** and **EGC-M5**.
- EGC-M4** is shown as a dihydroxybenzoic acid derivative.
- EGC-M5** is a cyclic ether intermediate.
- EGC-M5** is converted into **EGC-M5-GlcUA** (conjugated with Glucuronic acid).
- EGC-M5-GlcUA** leads to two outcomes:
 - PERMEABILIDAD BARRERA HEMATOENCEFÁLICA** (Blood-brain barrier permeability).
 - NEURITOGÉNESIS CELULAS SH-SY5Y** (Neurogenesis in SH-SY5Y cells).

Figure 2. Mechanism of EGCG metabolite generation in the intestinal microbiota. Reciprocal interactions between EGCG and human gut microbiota in vitro [65].

3.4. Liposomal EGCG

However, it is crucial to understand the metabolic process and bioavailability of green tea catechins and EGCG, particularly in assessing their biological activity and comprehending their beneficial effects on human health. EGCG presents significantly lower bioavailability compared to other components of catechins [156,157]. Therefore, when assessing the activity of EGCG and its metabolites, it is essential to emphasize that their applications are greatly limited due to their low solubility, bioavailability, and stability. The use of liposomal formulations may serve as an effective strategy for their administration in autism. Liposomal delivery aims to improve the poor stability of polyphenols against temperature, light, pH, and oxygen [28,29], as well as their low permeability across intestinal membranes, which results in only a small proportion of these compounds remaining available for absorption in the human body after ingestion [29,30]. Both stability and oral bioavailability are enhanced via liposomal encapsulation, as it provides protection against degradation when passing through the gastrointestinal tract [31]. Moreover, nanotechnology can promote the controlled release of the polyphenol and modulate the interaction between polyphenols and the microbiota, which also represents an intriguing approach [31], and it has been seen that EGCG has significantly improved stability when formulated as dual-drug-loaded PEGylated PLGA nanoparticles (EGCG/AA NPs). Following oral administration in mice, EGCG accumulated in all major organs, including the brain, leading to an increase in synapse formation and a reduction in neuroinflammation in Alzheimer's disease [158].

These results seem to support the increase in EGCG activity when administered in a liposomal form, particularly enhancing its neuroprotective activity as seen in both in vivo and in vitro models of Parkinson's disease [159]. Furthermore, concerning its metabolites and their administration using nanotechnology, Abbasalipour H. et al. (2022) studied the neuroprotective effects of gallic acid on oxidative stress-induced cognitive impairment and the expression of the Nrf2/Keap1 gene in an autism model. Gallic acid-loaded nanophytosomes (GNP) were administered, and the results revealed improvements in learning and memory deficits by reducing oxidative stress, enhancing antioxidant enzyme activity, and modulating the Keap1/Nrf2 gene expression [160].

3.5. Potential Adverse Effects of EGCG

Green tea and, to a lesser extent, black tea are not only the main sources of EGCG but also contain other molecules such as caffeine. It is noteworthy that caffeine consumption has been specifically linked to an increase in sleep disturbances, characteristic of this population [161], as well as the presence of maladaptive behavior in children with ASD [162]. Furthermore, concerning the microbiota in individuals vulnerable to *Clostridium difficile* infections, an increased risk in such infections has been associated with tea consumption, as it disrupts the normal microbiome and promotes the overgrowth of facultative pathogens [163]. Tea consumption has also been identified as a risk factor for gastroesophageal reflux disease (GERD) [164], which is relevant considering that GERD is one of the gastrointestinal symptoms commonly described as ASD [165]. Moreover, excessive consumption of EGCG has been found to be hepatotoxic [166–168].

Despite these considerations, tea has been consumed worldwide for many centuries, and the intake of its main catechin, EGCG, has been shown to be particularly safe even at doses up to 800 mg/day [169]. Thus, consuming tea at appropriate doses presents significant health benefits and is highly safe in terms of potential adverse effects or contraindications [170].

4. Conclusions

ASD is a complex disorder characterized by inflammatory processes, high oxidative stress, and gastrointestinal disturbances. These issues may be attributed to changes in the intestinal microbiome, resulting in microbial dysbiosis in children with ASD. Polyphenols have demonstrated sufficient antioxidant and anti-inflammatory capacity to counteract

ASD symptoms. Their role in dysbiosis has also been studied, revealing their ability to regulate and improve the percentages of beneficial microbial species, thereby enhancing the pathology of ASD and promoting gut–brain axis function, consequently improving brain function. In this regard, EGCG appears particularly effective in improving microbial species and increasing the production of metabolites involved in maintaining epithelial integrity. It also demonstrates effectiveness in reducing inflammation directly linked to ASD by influencing specific pro-inflammatory cytokine levels and reducing oxidative stress. Furthermore, it can modulate the altered metabolic production in ASD by decreasing toxic metabolites such as p-cresol. All of these factors have an impact on brain function, which could provide significant benefits for children with ASD. However, it should be noted that these polyphenols have limitations in terms of intestinal assimilation and bioavailability. Hence, when considering the advantages of nanotechnology in overcoming these limitations, the administration of EGCG in liposomal form could potentially be more effective. Therefore, a future line of research could be to determine if the efficacy of liposomal EGCG is improved when administered as a complementary treatment for ASD.

Consequently, this review identifies EGCG liposomes as a potential adjunctive therapy for children with ASD, aiming to improve their quality of life and alleviate their symptoms.

Author Contributions: Conceptualization, J.E.d.I.R.O. and A.B.C.-S.; Writing—Original Draft Preparation, J.E.d.I.R.O., A.B.C.-S., M.B., B.P., C.M., P.S.-B., G.C., R.B.-B. and M.M.-M.; writing—review and editing, J.E.d.I.R.O., A.B.C.-S. and M.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported economically by the Catholic University of Valencia San Vicente Mártir.

Data Availability Statement: Not applicable due to data privacy.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Taylor, M.J.; Rosenqvist, M.A.; Larsson, H.; Gillberg, C.; D’Onofrio, B.M.; Lichtenstein, P.; Lundström, S. Etiology of Autism Spectrum Disorders and Autistic Traits Over Time. *JAMA Psychiatry* **2020**, *77*, 936–943. [CrossRef] [PubMed]
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed.; 2013; American Psychiatric Association: Washington, DC, USA. Available online: <https://dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596> (accessed on 18 May 2013).
3. Hughes, H.K.; Rose, D.; Ashwood, P. The Gut Microbiota and Dysbiosis in Autism Spectrum Disorders. *Curr. Neurol. Neurosci. Rep.* **2018**, *18*, 81. [CrossRef]
4. Maenner, M.J.; Warren, Z.; Williams, A.R.; Amoakohene, E.; Bakian, A.V.; Bilder, D.A.; Durkin, M.S.; Fitzgerald, R.T.; Furnier, S.M.; Hughes, M.M.; et al. Prevalence and Characteristics of Autism Spectrum Disorder among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. *MMWR Surveill. Summ.* **2023**, *72*, 1–14. [CrossRef]
5. Grimaldi, R.; Gibson, G.R.; Vulevic, J.; Giallourou, N.; Castro-Mejía, J.L.; Hansen, L.H.; Leigh Gibson, E.; Nielsen, D.S.; Costabile, A. A Prebiotic Intervention Study in Children with Autism Spectrum Disorders (ASDs). *Microbiome* **2018**, *6*, 133. [CrossRef]
6. World Health Organization. Autism. Available online: <https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders> (accessed on 26 February 2023).
7. Li, Q.; Zhou, J.M. The Microbiota–Gut–Brain Axis and Its Potential Therapeutic Role in Autism Spectrum Disorder. *Neuroscience* **2016**, *324*, 131–139. [CrossRef]
8. Yang, J.; Fu, X.; Liao, X.; Li, Y. Effects of Gut Microbial-Based Treatments on Gut Microbiota, Behavioral Symptoms, and Gastrointestinal Symptoms in Children with Autism Spectrum Disorder: A Systematic Review. *Psychiatry Res.* **2020**, *293*, 113471. [CrossRef]
9. de Theije, C.G.M.; Wopereis, H.; Ramadan, M.; van Eijndthoven, T.; Lambert, J.; Knol, J.; Garssen, J.; Kraneveld, A.D.; Oozeer, R. Altered Gut Microbiota and Activity in a Murine Model of Autism Spectrum Disorders. *Brain Behav. Immun.* **2014**, *37*, 197–206. [CrossRef]
10. Strati, F.; Cavalieri, D.; Albanese, D.; De Felice, C.; Donati, C.; Hayek, J.; Jousson, O.; Leoncini, S.; Renzi, D.; Calabrò, A.; et al. New Evidences on the Altered Gut Microbiota in Autism Spectrum Disorders. *Microbiome* **2017**, *5*, 24. [CrossRef]
11. Huttenhower, C.; Gevers, D.; Knight, R.; Abubucker, S.; Badger, J.H.; Chinwalla, A.T.; Creasy, H.H.; Earl, A.M.; Fitzgerald, M.G.; Fulton, R.S.; et al. Structure, Function and Diversity of the Healthy Human Microbiome. *Nature* **2012**, *486*, 207–214. [CrossRef]

12. Rinninella, E.; Raoul, P.; Cintoni, M.; Franceschi, F.; Miggiano, G.A.D.; Gasbarrini, A.; Mele, M.C. What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms* **2019**, *7*, 14. [\[CrossRef\]](#)
13. Iovene, M.R.; Bombace, F.; Maresca, R.; Sapone, A.; Iardino, P.; Picardi, A.; Marotta, R.; Schiraldi, C.; Siniscalco, D.; Serra, N.; et al. Intestinal Dysbiosis and Yeast Isolation in Stool of Subjects with Autism Spectrum Disorders. *Mycopathologia* **2017**, *182*, 349–363. [\[CrossRef\]](#)
14. Yadav, M.; Kapoor, A.; Verma, A.; Ambatipudi, K. Functional Significance of Different Milk Constituents in Modulating the Gut Microbiome and Infant Health. *J. Agric. Food Chem.* **2022**, *70*, 3929–3947. [\[CrossRef\]](#)
15. Ding, H.; Yi, X.; Zhang, X.; Wang, H.; Liu, H.; Mou, W.W. Imbalance in the Gut Microbiota of Children with Autism Spectrum Disorders. *Front. Cell. Infect. Microbiol.* **2021**, *11*, 496. [\[CrossRef\]](#)
16. Heijtz, R.D.; Wang, S.; Anuar, F.; Qian, Y.; Björkholm, B.; Samuelsson, A.; Hibberd, M.L.; Forssberg, H.; Pettersson, S. Normal Gut Microbiota Modulates Brain Development and Behavior. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 3047–3052. [\[CrossRef\]](#)
17. Hooper, L.V.; Littman, D.R.; Macpherson, A.J. Interactions between the Microbiota and the Immune System. *Science (80-)* **2012**, *336*, 1268–1273. [\[CrossRef\]](#)
18. Frye, R.E.; Melnyk, S.; Macfabe, D.F. Unique Acyl-Carnitine Profiles Are Potential Biomarkers for Acquired Mitochondrial Disease in Autism Spectrum Disorder. *Transl. Psychiatry* **2013**, *3*, e220. [\[CrossRef\]](#)
19. Slattery, J.; Macfabe, D.F.; Frye, R.E. The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood. *Clin. Med. Insights Pediatr.* **2016**, *10*, CMPed.S38338. [\[CrossRef\]](#)
20. Zhang, L.; Xu, Y.; Li, H.; Li, B.; Duan, G.; Zhu, C. The Role of Probiotics in Children with Autism Spectrum Disorders: A Study Protocol for a Randomised Controlled Trial. *PLoS ONE* **2022**, *17*, e0263109. [\[CrossRef\]](#)
21. Grenham, S.; Clarke, G.; Cryan, J.F.; Dinan, T.G. Brain-Gut-Microbe Communication in Health and Disease. *Front. Physiol.* **2011**, *2*, 94. [\[CrossRef\]](#)
22. Jiang, C.; Li, G.; Huang, P.; Liu, Z.; Zhao, B. The Gut Microbiota and Alzheimer’s Disease. *J. Alzheimer’s Dis.* **2017**, *58*, 1–15. [\[CrossRef\]](#)
23. Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The Gut-Brain Axis: Interactions between Enteric Microbiota, Central and Enteric Nervous Systems. *Ann. Gastroenterol.* **2015**, *28*, 203–209.
24. Barrett, E.; Ross, R.P.; O’Toole, P.W.; Fitzgerald, G.F.; Stanton, C. γ -Aminobutyric Acid Production by Culturable Bacteria from the Human Intestine. *J. Appl. Microbiol.* **2012**, *113*, 411–417. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Serra, D.; Almeida, L.M.; Dinis, T.C.P. Polyphenols in the Management of Brain Disorders: Modulation of the Microbiota-Gut-Brain Axis. *Adv. Food Nutr. Res.* **2020**, *91*, 1–27. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Powell, N.; Walker, M.M.; Talley, N.J. The Mucosal Immune System: Master Regulator of Bidirectional Gut-Brain Communications. *Nat. Rev. Gastroenterol. Hepatol.* **2017**, *14*, 143–159. [\[CrossRef\]](#)
27. Sun, Q.; Cheng, L.; Zhang, X.; Wu, Z.; Weng, P. The Interaction between Tea Polyphenols and Host Intestinal Microorganisms: An Effective Way to Prevent Psychiatric Disorders. *Food Funct.* **2021**, *12*, 952–962. [\[CrossRef\]](#)
28. Argou-Cardozo, I.; Zeidán-Chuliá, F. Clostridium Bacteria and Autism Spectrum Conditions: A Systematic Review and Hypothetical Contribution of Environmental Glyphosate Levels. *Med. Sci.* **2018**, *6*, 29. [\[CrossRef\]](#) [\[PubMed\]](#)
29. Xu, M.; Xu, X.; Li, J.; Li, F. Association between Gut Microbiota and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *Front. Psychiatry* **2019**, *10*, 473. [\[CrossRef\]](#)
30. Zou, R.; Xu, F.; Wang, Y.; Duan, M.; Guo, M.; Zhang, Q.; Zhao, H.; Zheng, H. Changes in the Gut Microbiota of Children with Autism Spectrum Disorder. *Autism Res.* **2020**, *13*, 1614–1625. [\[CrossRef\]](#)
31. De Angelis, M.; Piccolo, M.; Vannini, L.; Siragusa, S.; De Giacomo, A.; Serrazanetti, D.I.; Cristofori, F.; Guerzoni, M.E.; Gobbetti, M.; Francavilla, R. Fecal Microbiota and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified. *PLoS ONE* **2013**, *8*, e76993. [\[CrossRef\]](#)
32. Andreo-Martínez, P.; García-Martínez, N.; Sánchez-Samper, E.P.; Martínez-González, A.E. An Approach to Gut Microbiota Profile in Children with Autism Spectrum Disorder. *Environ. Microbiol. Rep.* **2020**, *12*, 115–135. [\[CrossRef\]](#)
33. Tomova, A.; Husarova, V.; Lakatosova, S.; Bakos, J.; Vlkova, B.; Babinska, K.; Ostatnikova, D. Gastrointestinal Microbiota in Children with Autism in Slovakia. *Physiol. Behav.* **2015**, *138*, 179–187. [\[CrossRef\]](#)
34. Xie, X.; Li, L.; Wu, X.; Hou, F.; Chen, Y.; Shi, L.; Liu, Q.; Zhu, K.; Jiang, Q.; Feng, Y.; et al. Alteration of the Fecal Microbiota in Chinese Children with Autism Spectrum Disorder. *Autism Res.* **2022**, *15*, 996–1007. [\[CrossRef\]](#)
35. Williams, B.L.; Hornig, M.; Buie, T.; Bauman, M.L.; Cho Paik, M.; Wick, I.; Bennett, A.; Jabado, O.; Hirschberg, D.L.; Lipkin, W.I. Impaired Carbohydrate Digestion and Transport and Mucosal Dysbiosis in the Intestines of Children with Autism and Gastrointestinal Disturbances. *PLoS ONE* **2011**, *6*, e24585. [\[CrossRef\]](#)
36. Gondalia, S.V.; Palombo, E.A.; Knowles, S.R.; Cox, S.B.; Meyer, D.; Austin, D.W. Molecular Characterisation of Gastrointestinal Microbiota of Children with Autism (with and without Gastrointestinal Dysfunction) and Their Neurotypical Siblings. *Autism Res.* **2012**, *5*, 419–427. [\[CrossRef\]](#)
37. Son, J.S.; Zheng, L.J.; Rowehl, L.M.; Tian, X.; Zhang, Y.; Zhu, W.; Litcher-Kelly, L.; Gadow, K.D.; Gathungu, G.; Robertson, C.E.; et al. Comparison of Fecal Microbiota in Children with Autism Spectrum Disorders and Neurotypical Siblings in the Simons Simplex Collection. *PLoS ONE* **2015**, *10*, e0137725. [\[CrossRef\]](#)

38. Ho, L.K.H.; Tong, V.J.W.; Syn, N.; Nagarajan, N.; Tham, E.H.; Tay, S.K.; Shorey, S.; Tambyah, P.A.; Law, E.C.N. Gut Microbiota Changes in Children with Autism Spectrum Disorder: A Systematic Review. *Gut Pathog.* **2020**, *12*, 6. [\[CrossRef\]](#) [\[PubMed\]](#)
39. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poulet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of Diet in Shaping Gut Microbiota Revealed by a Comparative Study in Children from Europe and Rural Africa. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 14691–14696. [\[CrossRef\]](#) [\[PubMed\]](#)
40. Nogay, N.H.; Nahikian-Nelms, M. Can We Reduce Autism-Related Gastrointestinal and Behavior Problems by Gut Microbiota Based Dietary Modulation? A Review. *Nutr. Neurosci.* **2021**, *24*, 327–338. [\[CrossRef\]](#) [\[PubMed\]](#)
41. Cheng, N.; Rho, J.M.; Masino, S.A. Metabolic Dysfunction Underlying Autism Spectrum Disorder and Potential Treatment Approaches. *Front. Mol. Neurosci.* **2017**, *10*, 34. [\[CrossRef\]](#)
42. Serra, D.; Almeida, L.M.; Dinis, T.C.P. Polyphenols as Food Bioactive Compounds in the Context of Autism Spectrum Disorders: A Critical Mini-Review. *Neurosci. Biobehav. Rev.* **2019**, *102*, 290–298. [\[CrossRef\]](#)
43. Pérez-Burillo, S.; Navajas-Porras, B.; López-Maldonado, A.; Hinojosa-Nogueira, D.; Pastoriza, S.; Rufián-Henares, J.Á. Green Tea and Its Relation to Human Gut Microbiome. *Molecules* **2021**, *26*, 3907. [\[CrossRef\]](#)
44. Liu, Z.; Bruins, M.E.; Ni, L.; Vincken, J.P. Green and Black Tea Phenolics: Bioavailability, Transformation by Colonic Microbiota, and Modulation of Colonic Microbiota. *J. Agric. Food Chem.* **2018**, *66*, 8469–8477. [\[CrossRef\]](#)
45. Francisco, A.; Tomás-Barberán, González-Sarrias, A.; García-Villalba, R. *Dietary Polyphenols: Metabolism and Health Effects*; Wiley-Blackwell: Murcia, Spain, 2020.
46. Peterson, J.; Dwyer, J.; Bhagwat, S.; Haytowitz, D.; Holden, J.; Eldridge, A.L.; Beecher, G.; Aladesanmi, J. Major Flavonoids in Dry Tea. *J. Food Compos. Anal.* **2005**, *18*, 487–501. [\[CrossRef\]](#)
47. Ankolekar, C.; Johnson, D.; Pinto, M.D.S.; Johnson, K.; Labbe, R.; Shetty, K. Inhibitory Potential of Tea Polyphenolics and Influence of Extraction Time against *Helicobacter Pylori* and Lack of Inhibition of Beneficial Lactic Acid Bacteria. *J. Med. Food* **2011**, *14*, 1321–1329. [\[CrossRef\]](#) [\[PubMed\]](#)
48. Shin, J.S.; Chung, H.S. Antibacterial Activities of Phenolic Components from *Camellia Sinensis* L. on Pathogenic Microorganisms. *Prev. Nutr. Food Sci.* **2007**, *12*, 135–140. [\[CrossRef\]](#)
49. Nakayama, M.; Shigemune, N.; Tsugukuni, T.; Jun, H.; Matsushita, T.; Mekada, Y.; Kurahachi, M.; Miyamoto, T. Mechanism of the Combined Anti-Bacterial Effect of Green Tea Extract and NaCl against *Staphylococcus Aureus* and *Escherichia Coli* O157:H7. *Food Control* **2012**, *25*, 225–232. [\[CrossRef\]](#)
50. Kohda, C.; Yanagawa, Y.; Shimamura, T. Epigallocatechin Gallate Inhibits Intracellular Survival of *Listeria Monocytogenes* in Macrophages. *Biochem. Biophys. Res. Commun.* **2008**, *365*, 310–315. [\[CrossRef\]](#)
51. Si, W.; Gong, J.; Tsao, R.; Kalab, M.; Yang, R.; Yin, Y. Bioassay-Guided Purification and Identification of Antimicrobial Components in Chinese Green Tea Extract. *J. Chromatogr. A* **2006**, *1125*, 204–210. [\[CrossRef\]](#)
52. Bancirova, M. Comparison of the Antioxidant Capacity and the Antimicrobial Activity of Black and Green Tea. *Food Res. Int.* **2010**, *43*, 1379–1382. [\[CrossRef\]](#)
53. Liu, S.; Lu, H.; Zhao, Q.; He, Y.; Niu, J.; Debnath, A.K.; Wu, S.; Jiang, S. Theaflavin Derivatives in Black Tea and Catechin Derivatives in Green Tea Inhibit HIV-1 Entry by Targeting Gp41. *Biochim. Biophys. Acta* **2005**, *1723*, 270–281. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Chen, Y.L.; Tsai, H.L.; Peng, C.W. EGCG Debilitates the Persistence of EBV Latency by Reducing the DNA Binding Potency of Nuclear Antigen 1. *Biochem. Biophys. Res. Commun.* **2012**, *417*, 1093–1099. [\[CrossRef\]](#)
55. Duda-Chodak, A.; Tarko, P.; Satora, P.; Sroka, P. Interaction of Dietary Compounds, Especially Polyphenols, with the Intestinal Microbiota: A Review. *Eur. J. Nutr.* **2015**, *54*, 325–341. [\[CrossRef\]](#)
56. Nagle, D.G.; Ferreira, D.; Zhou, Y.D. Epigallocatechin-3-Gallate (EGCG): Chemical and Biomedical Perspectives. *Phytochemistry* **2006**, *67*, 1849–1855. [\[CrossRef\]](#) [\[PubMed\]](#)
57. Trovò, L.; Fuchs, C.; De Rosa, R.; Barbiero, I.; Tramarin, M.; Ciani, E.; Rusconi, L.; Kilstrup-Nielsen, C. The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) Restores CDKL5-Dependent Synaptic Defects in Vitro and in Vivo. *Neurobiol. Dis.* **2020**, *138*, 104791. [\[CrossRef\]](#) [\[PubMed\]](#)
58. Kumaravel, P.; Melchias, G.; Vasanth, N.; Manivasagam, T. Dose-Dependent Amelioration of Epigallocatechin-3-Gallate against Sodium Valproate Induced Autistic Rats. *Int. J. Pharm. Pharm. Sci.* **2017**, *9*, 203–206. [\[CrossRef\]](#)
59. Taliou, A.; Zintzaras, E.; Lykouras, L.; Francis, K. An Open-Label Pilot Study of a Formulation Containing the Anti-Inflammatory Flavonoid Luteolin and Its Effects on Behavior in Children with Autism Spectrum Disorders. *Clin. Ther.* **2013**, *35*, 592–602. [\[CrossRef\]](#) [\[PubMed\]](#)
60. Tsilioni, I.; Taliou, A.; Francis, K.; Theoharides, T.C. Children with Autism Spectrum Disorders, Who Improved with a Luteolin-Containing Dietary Formulation, Show Reduced Serum Levels of TNF and IL-6. *Transl. Psychiatry* **2015**, *5*, e647. [\[CrossRef\]](#)
61. Bertolino, B.; Crupi, R.; Impellizzeri, D.; Bruschetta, G.; Cordaro, M.; Siracusa, R.; Esposito, E.; Cuzzocrea, S. Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism. *CNS Neurosci. Ther.* **2017**, *23*, 87–98. [\[CrossRef\]](#)
62. Nasiry, D.; Khalatbary, A.R. Natural Polyphenols for the Management of Autism Spectrum Disorder: A Review of Efficacy and Molecular Mechanisms. *Nutr. Neurosci.* **2023**, *2023*, 1–11. [\[CrossRef\]](#)
63. Scholey, A.; Downey, L.A.; Ciorciari, J.; Pipingas, A.; Nolidin, K.; Finn, M.; Wines, M.; Catchlove, S.; Terrens, A.; Barlow, E.; et al. Acute Neurocognitive Effects of Epigallocatechin Gallate (EGCG). *Appetite* **2012**, *58*, 767–770. [\[CrossRef\]](#)

64. Lee, H.C.; Jenner, A.M.; Low, C.S.; Lee, Y.K. Effect of Tea Phenolics and Their Aromatic Fecal Bacterial Metabolites on Intestinal Microbiota. *Res. Microbiol.* **2006**, *157*, 876–884. [\[CrossRef\]](#)
65. Liu, Z.; De Bruijn, W.J.C.; Bruins, M.E.; Vincken, J.P. Reciprocal Interactions between Epigallocatechin-3-Gallate (EGCG) and Human Gut Microbiota in Vitro. *J. Agric. Food Chem.* **2020**, *68*, 9804–9815. [\[CrossRef\]](#)
66. Xu, Y.; Xie, M.; Xue, J.; Xiang, L.; Li, Y.; Xiao, J.; Xiao, G.; Wang, H.L. EGCG Ameliorates Neuronal and Behavioral Defects by Remodeling Gut Microbiota and TotM Expression in Drosophila Models of Parkinson's Disease. *FASEB J.* **2020**, *34*, 5931–5950. [\[CrossRef\]](#)
67. Ushiroda, C.; Naito, Y.; Takagi, T.; Uchiyama, K.; Mizushima, K.; Higashimura, Y.; Yasukawa, Z.; Okubo, T.; Inoue, R.; Honda, A.; et al. Green Tea Polyphenol (Epigallocatechin-3-Gallate) Improves Gut Dysbiosis and Serum Bile Acids Dysregulation in High-Fat Diet-Fed Mice. *J. Clin. Biochem. Nutr.* **2019**, *65*, 34–46. [\[CrossRef\]](#) [\[PubMed\]](#)
68. Qu, Y.; Wu, Y.; Cheng, W.; Wang, D.; Zeng, L.; Wang, Y.; Li, T.-T.; Zhang, L.; Yang, J.; Sun, L.; et al. Amelioration of Cognitive Impairment Using Epigallocatechin-3-Gallate in Ovariectomized Mice Fed a High-Fat Diet Involves Remodeling with Prevotella and Bifidobacteriales. *Front. Pharmacol.* **2023**, *13*, 1079313. [\[CrossRef\]](#) [\[PubMed\]](#)
69. Mastromarino, P.; Capobianco, D.; Campagna, G.; Laforgia, N.; Drimaco, P.; Dileone, A.; Baldassarre, M.E. Correlation between Lactoferrin and Beneficial Microbiota in Breast Milk and Infant's Feces. *Biomaterials* **2014**, *27*, 1077–1086. [\[CrossRef\]](#)
70. Savignac, H.M.; Kiely, B.; Dinan, T.G.; Cryan, J.F. Bifidobacteria Exert Strain-Specific Effects on Stress-Related Behavior and Physiology in BALB/c Mice. *Neurogastroenterol. Motil.* **2014**, *26*, 1615–1627. [\[CrossRef\]](#)
71. Andreo-Martínez, P.; Martínez-González, A.E. Una Propuesta de Probiótico Basada En El Bifidobacterium Para Autismo. *Rev. Española Nutr. Humana Y Dietética* **2022**, *26* (Suppl. S1), e1429. [\[CrossRef\]](#)
72. Unno, T.; Sakuma, M.; Mitsuhashi, S. Effect of Dietary Supplementation of (-)-Epigallocatechin Gallate on Gut Microbiota and Biomarkers of Colonic Fermentation in Rats. *J. Nutr. Sci. Vitaminol.* **2014**, *60*, 213–219. [\[CrossRef\]](#)
73. Tarek El-Banna; El-Aziz, A. A.; EL-Mahdy, N.; Samy, Y. *Sherrie Medical Microbiology*, 4th ed.; McGraw-Hill: New York, NY, USA, 2004.
74. Pérez de Rozas Ruiz de Gauna, A.M.; Badiola Sáiz, I.; Castellà Gómez, G.; Universitat Autònoma de Barcelona; Departament de Sanitat i d'Anatomia Animals; Centre de Recerca de Sanitat Animal. Institut de Recerca i Tecnologia Agroalimentàries. Utilització de Cepas de *Bacteroides* Spp. Como Probiótico En Conejos. TDX (Tesis Dr. en Xarxa). Ph.D. Thesis, Universitat Autònoma de Barcelona, Catalonia, Spain, 2014.
75. Jiang, C.C.; Lin, L.S.; Long, S.; Ke, X.Y.; Fukunaga, K.; Lu, Y.M.; Han, F. Signalling Pathways in Autism Spectrum Disorder: Mechanisms and Therapeutic Implications. *Signal Transduct. Target. Ther.* **2022**, *7*, 229. [\[CrossRef\]](#)
76. Xu, X.J.; Lang, J.D.; Yang, J.; Long, B.; Liu, X.D.; Zeng, X.F.; Tian, G.; You, X. Differences of Gut Microbiota and Behavioral Symptoms between Two Subgroups of Autistic Children Based on $\gamma\delta$ T Cells-Derived IFN- γ Levels: A Preliminary Study. *Front. Immunol.* **2023**, *14*, 1100816. [\[CrossRef\]](#)
77. Saitoh, S.; Noda, S.; Aiba, Y.; Takagi, A.; Sakamoto, M.; Benno, Y.; Koga, Y. *Bacteroides* *Ovatus* as the Predominant Commensal Intestinal Microbe Causing a Systemic Antibody Response in Inflammatory Bowel Disease. *Clin. Diagn. Lab. Immunol.* **2002**, *9*, 54–59. [\[CrossRef\]](#)
78. Srikantha, P.; Hasan Mohajeri, M. The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder. *Int. J. Mol. Sci.* **2019**, *20*, 2115. [\[CrossRef\]](#)
79. Tett, A.; Huang, K.D.; Asnicar, F.; Fehlner-Peach, H.; Pasolli, E.; Karcher, N.; Armanini, F.; Manghi, P.; Bonham, K.; Zolfo, M.; et al. The Prevotella Copri Complex Comprises Four Distinct Clades Underrepresented in Westernized Populations. *Cell Host Microbe* **2019**, *26*, 666–679.e7. [\[CrossRef\]](#) [\[PubMed\]](#)
80. O'Grady, J.; O'Connor, E.M.; Shanahan, F. Review Article: Dietary Fibre in the Era of Microbiome Science. *Aliment. Pharmacol. Ther.* **2019**, *49*, 506–515. [\[CrossRef\]](#) [\[PubMed\]](#)
81. Matusheski, N.V.; Caffrey, A.; Christensen, L.; Mezgec, S.; Surendran, S.; Hjorth, M.F.; McNulty, H.; Pentieva, K.; Roager, H.M.; Seljak, B.K.; et al. Diets, Nutrients, Genes and the Microbiome: Recent Advances in Personalised Nutrition. *Br. J. Nutr.* **2021**, *126*, 1489–1497. [\[CrossRef\]](#)
82. Ortega-Santos, C.P.; Whisner, C.M. The Key to Successful Weight Loss on a High-Fiber Diet May Be in Gut Microbiome Prevotella Abundance. *J. Nutr.* **2019**, *149*, 2083–2084. [\[CrossRef\]](#)
83. Hill, A.P.; Zuckerman, K.E.; Fombonne, E. Obesity and Autism. *Pediatrics* **2015**, *136*, 1051–1061. [\[CrossRef\]](#)
84. Sharp, W.G.; Postorino, V.; McCracken, C.E.; Berry, R.C.; Criado, K.K.; Burrell, T.L.; Scallion, L. Dietary Intake, Nutrient Status, and Growth Parameters in Children with Autism Spectrum Disorder and Severe Food Selectivity: An Electronic Medical Record Review. *J. Acad. Nutr. Diet.* **2018**, *118*, 1943–1950. [\[CrossRef\]](#) [\[PubMed\]](#)
85. Dhir, S.; Tarasenko, M.; Napoli, E.; Giulivi, C. Neurological, Psychiatric, and Biochemical Aspects of Thiamine Deficiency in Children and Adults. *Front. Psychiatry* **2019**, *10*, 207. [\[CrossRef\]](#) [\[PubMed\]](#)
86. Dandachi, I.; Anani, H.; Hadjadj, L.; Brahimi, S.; Lagier, J.C.; Daoud, Z.; Rolain, J.M. Genome Analysis of *Lachnospirillum* *Phocaense* Isolated from a Patient after Kidney Transplantation in Marseille. *New Microbes New Infect.* **2021**, *41*, 100863. [\[CrossRef\]](#) [\[PubMed\]](#)
87. McNabney, S.M.; Henagan, T.M. Short Chain Fatty Acids in the Colon and Peripheral Tissues: A Focus on Butyrate, Colon Cancer, Obesity and Insulin Resistance. *Nutrients* **2017**, *9*, 1348. [\[CrossRef\]](#)

88. Wu, Z.; Huang, S.; Li, T.; Li, N.; Han, D.; Zhang, B.; Xu, Z.Z.; Zhang, S.; Pang, J.; Wang, S.; et al. Gut Microbiota from Green Tea Polyphenol-Dosed Mice Improves Intestinal Epithelial Homeostasis and Ameliorates Experimental Colitis. *Microbiome* **2021**, *9*, 184. [CrossRef] [PubMed]
89. Wu, Z.; Huang, S.; Li, T.; Li, N.; Han, D.; Zhang, S.; Pang, J.; Wang, S.; Zhang, G.; Wang, J. Oral, but Not Rectal Delivery of Epigallocatechin-3-Gallate Alleviates Colitis by Regulating the Gut Microbiota, Oxidative Stress, Inflammation, and Barrier Integrity. *Res. Sq.* **2020**. [CrossRef]
90. Amaral Montesino, C.; Abrego Sánchez, A.; Díaz Granados, M.A.; González Ponce, R.; Salinas Flores, A.; Rojas García, O.C. Akkermansia Muciniphila, Una Ventana de Investigación Para La Regulación Del Metabolismo y Enfermedades Relacionadas. *Nutr. Hosp.* **2021**, *38*, 675–676. [CrossRef]
91. Chang, Y.; Yang, Y.; Xu, N.; Mu, H.; Zhang, H.; Duan, J. Improved Viability of Akkermansia Muciniphila by Encapsulation in Spray Dried Succinate-Grafted Alginate Doped with Epigallocatechin-3-Gallate. *Int. J. Biol. Macromol.* **2020**, *159*, 373–382. [CrossRef]
92. Sheng, L.; Jena, P.K.; Hui-Xin, L.; Hu, Y.; Nagar, N.; Bronner, D.N.; Settles, M.L.; Bäuml, A.J.; Wan, Y.J.Y. Obesity Treatment by Epigallocatechin-3-Gallate—regulated Bile Acid Signaling and Its Enriched Akkermansia Muciniphila. *FASEB J.* **2018**, *32*, 6371–6384. [CrossRef]
93. Liu, X.; Zhao, K.; Jing, N.; Zhao, Y.; Yang, X. EGCG Regulates Fatty Acid Metabolism of High-Fat Diet-Fed Mice in Association with Enrichment of Gut Akkermansia Muciniphila. *J. Funct. Foods* **2020**, *75*, 104261. [CrossRef]
94. Manrique, D.; Elie, V. Ácidos Grasos de Cadena Corta (Ácido Butírico) y Patologías Intestinales. *Nutr. Hosp.* **2017**, *34*, 58–61. [CrossRef]
95. Riviére, A.; Selak, M.; Lantin, D.; Leroy, F.; De Vuyst, L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front. Microbiol.* **2016**, *7*, 979. [CrossRef] [PubMed]
96. Alshammari, M.K.; AlKhulaifi, M.M.; Al Farraj, D.A.; Somily, A.M.; Albarrag, A.M. Incidence of Clostridium Perfringens and Its Toxin Genes in the Gut of Children with Autism Spectrum Disorder. *Anaerobe* **2020**, *61*, 102114. [CrossRef]
97. Liu, J.; Gao, Z.; Liu, C.; Liu, T.; Gao, J.; Cai, Y.; Fan, X. Alteration of Gut Microbiota: New Strategy for Treating Autism Spectrum Disorder. *Front. Cell Dev. Biol.* **2022**, *10*, 192. [CrossRef] [PubMed]
98. Sandler, R.H.; Finegold, S.M.; Bolte, E.R.; Buchanan, C.P.; Maxwell, A.P.; Väisänen, M.L.; Nelson, M.N.; Wexler, H.M. Short-Term Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism. *J. Child Neurol.* **2000**, *15*, 429–435. [CrossRef]
99. Enterobacterias—EcuRed. Available online: <https://www.ecured.cu/Enterobacterias> (accessed on 11 October 2022).
100. Mohammad, F.K.; Palukuri, M.V.; Shivakumar, S.; Rengaswamy, R.; Sahoo, S. A Computational Framework for Studying Gut-Brain Axis in Autism Spectrum Disorder. *Front. Physiol.* **2022**, *13*, 760753. [CrossRef] [PubMed]
101. Rossignol, D.A.; Frye, R.E. Mitochondrial Dysfunction in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. *Mol. Psychiatry* **2012**, *17*, 290–314. [CrossRef]
102. Matelski, L.; Van de Water, J. Risk Factors in Autism: Thinking Outside the Brain. *J. Autoimmun.* **2016**, *67*, 1–7. [CrossRef] [PubMed]
103. McAllister, A.K. Immune Contributions to Cause and Effect in Autism Spectrum Disorder. *Biol. Psychiatry* **2017**, *81*, 380–382. [CrossRef] [PubMed]
104. Meltzer, A.; Van De Water, J. The Role of the Immune System in Autism Spectrum Disorder. *Neuropsychopharmacology* **2017**, *42*, 284–298. [CrossRef]
105. Leviton, A.; Joseph, R.M.; Allred, E.N.; Fichorova, R.N.; O’Shea, T.M.; Kuban, K.K.C.; Dammann, O. The Risk of Neurodevelopmental Disorders at Age 10 Years Associated with Blood Concentrations of Interleukins 4 and 10 during the First Postnatal Month of Children Born Extremely Preterm. *Cytokine* **2018**, *110*, 181–188. [CrossRef]
106. Shen, Y.; Li, Y.; Shi, L.; Liu, M.; Wu, R.; Xia, K.; Zhang, F.; Ou, J.; Zhao, J. Autism Spectrum Disorder and Severe Social Impairment Associated with Elevated Plasma Interleukin-8. *Pediatr. Res.* **2021**, *89*, 591–597. [CrossRef]
107. Jyonouchi, H.; Geng, L.; Davidow, A.L. Cytokine Profiles by Peripheral Blood Monocytes Are Associated with Changes in Behavioral Symptoms Following Immune Insults in a Subset of ASD Subjects: An Inflammatory Subtype? *J. Neuroinflamm.* **2014**, *11*, 187. [CrossRef]
108. Jyonouchi, H.; Geng, L.; Streck, D.L.; Dermody, J.J.; Toruner, G.A. MicroRNA Expression Changes in Association with Changes in Interleukin-1 β /Interleukin10 Ratios Produced by Monocytes in Autism Spectrum Disorders: Their Association with Neuropsychiatric Symptoms and Comorbid Conditions (Observational Study). *J. Neuroinflamm.* **2017**, *14*, 229. [CrossRef]
109. Masi, A.; Quintana, D.S.; Glozier, N.; Lloyd, A.R.; Hickie, I.B.; Guastella, A.J. Cytokine Aberrations in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *Mol. Psychiatry* **2015**, *20*, 440–446. [CrossRef]
110. Ricci, S.; Businaro, R.; Ippoliti, F.; Lo Vasco, V.R.; Massoni, F.; Onofri, E.; Troili, G.M.; Pontecorvi, V.; Morelli, M.; Rapp Ricciardi, M.; et al. Altered Cytokine and BDNF Levels in Autism Spectrum Disorder. *Neurotox. Res.* **2013**, *24*, 491–501. [CrossRef]
111. Binder, D.K.; Scharfman, H.E. Brain-Derived Neurotrophic Factor. *Growth Factors* **2004**, *22*, 123–131. [CrossRef]
112. Huang, E.J.; Reichardt, L.F. Neurotrophins: Roles in Neuronal Development and Function. *Annu. Rev. Neurosci.* **2001**, *24*, 677. [CrossRef]
113. Bekinschtein, P.; Cammarota, M.; Katche, C.; Slipczuk, L.; Rossato, J.I.; Goldin, A.; Izquierdo, I.; Medina, J.H. BDNF Is Essential to Promote Persistence of Long-Term Memory Storage. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 2711–2716. [CrossRef]

114. Yamada, K.; Nabeshima, T. Brain-Derived Neurotrophic Factor/TrkB Signaling in Memory Processes. *J. Pharmacol. Sci.* **2003**, *91*, 267–270. [\[CrossRef\]](#)
115. Hu, T.; Dong, Y.; He, C.; Zhao, M.; He, Q. The Gut Microbiota and Oxidative Stress in Autism Spectrum Disorders (ASD). *Oxid. Med. Cell. Longev.* **2020**, *2020*, 8396708. [\[CrossRef\]](#)
116. Hu, J.; Lin, S.; Zheng, B.; Cheung, P.C.K. Short-Chain Fatty Acids in Control of Energy Metabolism. *Crit. Rev. Food Sci. Nutr.* **2018**, *58*, 1243–1249. [\[CrossRef\]](#)
117. Codina-Solà, M.; Rodríguez-Santiago, B.; Homs, A.; Santoyo, J.; Rigau, M.; Aznar-Lain, G.; Del Campo, M.; Gener, B.; Gabau, E.; Botella, M.P.; et al. Integrated Analysis of Whole-Exome Sequencing and Transcriptome Profiling in Males with Autism Spectrum Disorders. *Mol. Autism* **2015**, *6*, 21. [\[CrossRef\]](#)
118. Bjørklund, G.; Meguid, N.A.; El-Bana, M.A.; Tinkov, A.A.; Saad, K.; Dadar, M.; Hemimi, M.; Skalny, A.V.; Hosnedlová, B.; Kizek, R.; et al. Oxidative Stress in Autism Spectrum Disorder. *Mol. Neurobiol.* **2020**, *57*, 2314–2332. [\[CrossRef\]](#)
119. Nadeem, A.; Ahmad, S.F.; Attia, S.M.; AL-Ayadhi, L.Y.; Al-Harbi, N.O.; Bakheet, S.A. Dysregulated Enzymatic Antioxidant Network in Peripheral Neutrophils and Monocytes in Children with Autism. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2019**, *88*, 352–359. [\[CrossRef\]](#)
120. Messina, A.; Monda, V.; Sessa, F.; Valenzano, A.; Salerno, M.; Bitetti, I.; Precenzano, F.; Marotta, R.; Lavano, F.; Lavano, S.M.; et al. Sympathetic, Metabolic Adaptations, and Oxidative Stress in Autism Spectrum Disorders: How Far from Physiology? *Front. Physiol.* **2018**, *9*, 261. [\[CrossRef\]](#)
121. Fransen, M.; Nordgren, M.; Wang, B.; Apanasets, O. Role of Peroxisomes in ROS/RNS-Metabolism: Implications for Human Disease. *Biochim. Biophys. Acta* **2012**, *1822*, 1363–1373. [\[CrossRef\]](#)
122. Cipolla, C.M.; Lodhi, I.J. Peroxisomal Dysfunction in Age-Related Diseases. *Trends Endocrinol. Metab.* **2017**, *28*, 297–308. [\[CrossRef\]](#)
123. James, S.J.; Melnyk, S.; Jernigan, S.; Cleves, M.A.; Halsted, C.H.; Wong, D.H.; Cutler, P.; Bock, K.; Boris, M.; Bradstreet, J.J.; et al. Metabolic Endophenotype and Related Genotypes Are Associated with Oxidative Stress in Children with Autism. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* **2006**, *141B*, 947–956. [\[CrossRef\]](#)
124. Rose, S.; Bennuri, S.C.; Wynne, R.; Melnyk, S.; James, S.J.; Frye, R.E. Mitochondrial and Redox Abnormalities in Autism Lymphoblastoid Cells: A Sibling Control Study. *FASEB J.* **2017**, *31*, 904–909. [\[CrossRef\]](#)
125. Ray, B.; Long, J.M.; Sokol, D.K.; Lahiri, D.K. Increased Secreted Amyloid Precursor Protein- α (SAPP α) in Severe Autism: Proposal of a Specific, Anabolic Pathway and Putative Biomarker. *PLoS ONE* **2011**, *6*, e20405. [\[CrossRef\]](#)
126. Sokol, D.K.; Maloney, B.; Long, J.M.; Ray, B.; Lahiri, D.K. Autism, Alzheimer Disease, and Fragile X: APP, FMRP, and MGluR5 Are Molecular Links. *Neurology* **2011**, *76*, 1344–1352. [\[CrossRef\]](#)
127. Lahiri, D.K.; Sokol, D.K.; Erickson, C.; Ray, B.; Ho, C.Y.; Maloney, B. Autism as Early Neurodevelopmental Disorder: Evidence for an SAPP α -Mediated Anabolic Pathway. *Front. Cell. Neurosci.* **2013**, *7*, 94. [\[CrossRef\]](#)
128. Valenti, D.; de Bari, L.; de Rasmo, D.; Signorile, A.; Henrion-Caude, A.; Contestabile, A.; Vacca, R.A. The Polyphenols Resveratrol and Epigallocatechin-3-Gallate Restore the Severe Impairment of Mitochondria in Hippocampal Progenitor Cells from a Down Syndrome Mouse Model. *Biochim. Biophys. Acta* **2016**, *1862*, 1093–1104. [\[CrossRef\]](#)
129. Serra, D.; Paixão, J.; Nunes, C.; Dinis, T.C.P.; Almeida, L.M. Cyanidin-3-Glucoside Suppresses Cytokine-Induced Inflammatory Response in Human Intestinal Cells: Comparison with 5-Aminosalicylic Acid. *PLoS ONE* **2013**, *8*, 73001. [\[CrossRef\]](#)
130. Serra, D.; Rufino, A.T.; Mendes, A.F.; Almeida, L.M.; Dinis, T.C.P. Resveratrol Modulates Cytokine-Induced JAK/STAT Activation More Efficiently than 5-Aminosalicylic Acid: An In Vitro Approach. *PLoS ONE* **2014**, *9*, e109048. [\[CrossRef\]](#)
131. Sunand, K.; Mohan, G.K.; Bakshi, V. Synergetic Potential of Combination Probiotic Complex with Phytopharmaceuticals in Valproic Acid Induced Autism: Prenatal Model. *Int. J. Appl. Pharm. Sci. Res.* **2021**, *6*, 33–43. [\[CrossRef\]](#)
132. Avramovich-Tirosh, Y.; Reznichenko, L.; Amit, T.; Zheng, H.; Fridkin, M.; Weinreb, O.; Mandel, S.; Youdim, M. Neurorescue Activity, APP Regulation and Amyloid-Beta Peptide Reduction by Novel Multi-Functional Brain Permeable Iron-Chelating-Antioxidants, M-30 and Green Tea Polyphenol, EGCG. *Curr. Alzheimer Res.* **2007**, *4*, 403–411. [\[CrossRef\]](#)
133. Pogačnik, L.; Pirc, K.; Palmela, I.; Skrt, M.; Kwang, K.S.; Brites, D.; Brito, M.A.; Ulrih, N.P.; Silva, R.F.M. Potential for Brain Accessibility and Analysis of Stability of Selected Flavonoids in Relation to Neuroprotection in Vitro. *Brain Res.* **2016**, *1651*, 17–26. [\[CrossRef\]](#)
134. Porath, D.; Riegger, C.; Drewe, J.; Schwager, J. Epigallocatechin-3-Gallate Impairs Chemokine Production in Human Colon Epithelial Cell Lines. *J. Pharmacol. Exp. Ther.* **2005**, *315*, 1172–1180. [\[CrossRef\]](#)
135. Frye, R.E.; Rossignol, D.A. Mitochondrial Dysfunction Can Connect the Diverse Medical Symptoms Associated with Autism Spectrum Disorders. *Pediatr. Res.* **2011**, *69 Pt 2*, 41–47. [\[CrossRef\]](#)
136. Ming, X.; Stein, T.P.; Barnes, V.; Rhodes, N.; Guo, L. Metabolic Perturbance in Autism Spectrum Disorders: A Metabolomics Study. *J. Proteome Res.* **2012**, *11*, 5856–5862. [\[CrossRef\]](#)
137. Frye, R.E.; Rose, S.; Slattery, J.; MacFabe, D.F. Gastrointestinal Dysfunction in Autism Spectrum Disorder: The Role of the Mitochondria and the Enteric Microbiome. *Microb. Ecol. Health Dis.* **2015**, *26*, 27458. [\[CrossRef\]](#)
138. Sergeant, T.; Piront, N.; Meurice, J.; Toussaint, O.; Schneider, Y.J. Anti-Inflammatory Effects of Dietary Phenolic Compounds in an in Vitro Model of Inflamed Human Intestinal Epithelium. *Chem. Biol. Interact.* **2010**, *188*, 659–667. [\[CrossRef\]](#)
139. Agarwala, S.; Naik, B.; Ramachandra, N.B. Mucosa-Associated Specific Bacterial Species Disrupt the Intestinal Epithelial Barrier in the Autism Phenome. *Brain Behav. Immun.-Health* **2021**, *15*, 100269. [\[CrossRef\]](#)

140. DeSantis, T.Z.; Hugenholtz, P.; Larsen, N.; Rojas, M.; Brodie, E.L.; Keller, K.; Huber, T.; Dalevi, D.; Hu, P.; Andersen, G.L. Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB. *Appl. Environ. Microbiol.* **2006**, *72*, 5069–5072. [\[CrossRef\]](#)
141. Liu, S.; Li, E.; Sun, Z.; Fu, D.; Duan, G.; Jiang, M.; Yu, Y.; Mei, L.; Yang, P.; Tang, Y.; et al. Altered Gut Microbiota and Short Chain Fatty Acids in Chinese Children with Autism Spectrum Disorder. *Sci. Rep.* **2019**, *9*, 287. [\[CrossRef\]](#)
142. Zhang, M.; Ma, W.; Zhang, J.; He, Y.; Wang, J. Analysis of Gut Microbiota Profiles and Microbe-Disease Associations in Children with Autism Spectrum Disorders in China. *Sci. Rep.* **2018**, *8*, 13981. [\[CrossRef\]](#)
143. Brown, C.T.; Davis-Richardson, A.G.; Giongo, A.; Gano, K.A.; Crabb, D.B.; Mukherjee, N.; Casella, G.; Drew, J.C.; Ilonen, J.; Knip, M.; et al. Gut Microbiome Metagenomics Analysis Suggests a Functional Model for the Development of Autoimmunity for Type 1 Diabetes. *PLoS ONE* **2011**, *6*, e25792. [\[CrossRef\]](#)
144. Rose, S.; Bennuri, S.C.; Murray, K.F.; Buie, T.; Winter, H.; Frye, R.E. Mitochondrial Dysfunction in the Gastrointestinal Mucosa of Children with Autism: A Blinded Case-Control Study. *PLoS ONE* **2017**, *12*, e0186377. [\[CrossRef\]](#)
145. Rose, S.; Bennuri, S.C.; Davis, J.E.; Wynne, R.; Slaterry, J.C.; Tippet, M.; Delhey, L.; Melnyk, S.; Kahler, S.G.; MacFabe, D.F.; et al. Butyrate Enhances Mitochondrial Function during Oxidative Stress in Cell Lines from Boys with Autism. *Transl. Psychiatry* **2018**, *8*, 42. [\[CrossRef\]](#)
146. Cristiano, C.; Hoxha, E.; Lippiello, P.; Balbo, I.; Russo, R.; Tempia, F.; Miniaci, M.C. Maternal Treatment with Sodium Butyrate Reduces the Development of Autism-like Traits in Mice Offspring. *Biomed. Pharmacother.* **2022**, *156*, 113870. [\[CrossRef\]](#)
147. Kang, D.W.; Ilhan, Z.E.; Isern, N.G.; Hoyt, D.W.; Howsmon, D.P.; Shaffer, M.; Lozupone, C.A.; Hahn, J.; Adams, J.B.; Krajmalnik-Brown, R. Differences in Fecal Microbial Metabolites and Microbiota of Children with Autism Spectrum Disorders. *Anaerobe* **2018**, *49*, 121–131. [\[CrossRef\]](#)
148. Andriamihaja, M.; Lan, A.; Beaumont, M.; Audebert, M.; Wong, X.; Yamada, K.; Yin, Y.; Tomé, D.; Carrasco-Pozo, C.; Gotteland, M.; et al. The Deleterious Metabolic and Genotoxic Effects of the Bacterial Metabolite P-Cresol on Colonic Epithelial Cells. *Free Radic. Biol. Med.* **2015**, *85*, 219–227. [\[CrossRef\]](#)
149. Unno, T.; Ichitani, M. Epigallocatechin-3-Gallate Decreases Plasma and Urinary Levels of p-Cresol by Modulating Gut Microbiota in Mice. *ACS Omega* **2022**, *7*, 40034–40041. [\[CrossRef\]](#)
150. Unno, K.; Pervin, M.; Nakagawa, A.; Iguchi, K.; Hara, A.; Takagaki, A.; Nanjo, F.; Minami, A.; Nakamura, Y. Blood-Brain Barrier Permeability of Green Tea Catechin Metabolites and Their Neuritogenic Activity in Human Neuroblastoma SH-SY5Y Cells. *Mol. Nutr. Food Res.* **2017**, *61*, 1700294. [\[CrossRef\]](#)
151. Kohri, T.; Matsumoto, N.; Yamakawa, M.; Suzuki, M.; Nanjo, F.; Hara, Y.; Oku, N. Metabolic Fate of (–)-[4-3H]Epigallocatechin Gallate in Rats after Oral Administration. *Am. Chem. Soc.* **2001**, *49*, 4102–4112. [\[CrossRef\]](#)
152. Pervin, M.; Unno, K.; Nakagawa, A.; Takahashi, Y.; Iguchi, K.; Yamamoto, H.; Hoshino, M.; Hara, A.; Takagaki, A.; Nanjo, F.; et al. Blood Brain Barrier Permeability of (–)-Epigallocatechin Gallate, Its Proliferation-Enhancing Activity of Human Neuroblastoma SH-SY5Y Cells, and Its Preventive Effect on Age-Related Cognitive Dysfunction in Mice. *Biochem. Biophys. Rep.* **2017**, *9*, 180–186. [\[CrossRef\]](#)
153. Pervin, M.; Unno, K.; Takagaki, A.; Isemura, M.; Nakamura, Y. Function of Green Tea Catechins in the Brain: Epigallocatechin Gallate and Its Metabolites. *Int. J. Mol. Sci.* **2019**, *20*, 3630. [\[CrossRef\]](#)
154. Lambert, J.D.; Rice, J.E.; Hong, J.; Hou, Z.; Yang, C.S. Synthesis and Biological Activity of the Tea Catechin Metabolites, M4 and M6 and Their Methoxy-Derivatives. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 873–876. [\[CrossRef\]](#)
155. Kim, Y.H.; Won, Y.S.; Yang, X.; Kumazoe, M.; Yamashita, S.; Hara, A.; Takagaki, A.; Goto, K.; Nanjo, F.; Tachibana, H. Green Tea Catechin Metabolites Exert Immunoregulatory Effects on CD4(+) T Cell and Natural Killer Cell Activities. *J. Agric. Food Chem.* **2016**, *64*, 3591–3597. [\[CrossRef\]](#)
156. Chen, L.; Lee, M.-J.; Li, H.; Yang, C.S. Absorption, Distribution, and Elimination of Tea Polyphenols in Rats. *Drug Metab. Dispos.* **1997**, *25*, 1045–1050.
157. Kim, S.; Lee, M.J.; Hong, J.; Li, C.; Smith, T.J.; Yang, G.Y.; Seril, D.N.; Yang, C.S. Plasma and Tissue Levels of Tea Catechins in Rats and Mice during Chronic Consumption of Green Tea Polyphenols. *Nutr. Cancer* **2000**, *37*, 41–48. [\[CrossRef\]](#)
158. Cano, A.; Ettcheto, M.; Chang, J.H.; Barroso, E.; Espina, M.; Kühne, B.A.; Barenys, M.; Auladell, C.; Folch, J.; Souto, E.B.; et al. Dual-Drug Loaded Nanoparticles of Epigallocatechin-3-Gallate (EGCG)/Ascorbic Acid Enhance Therapeutic Efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's Disease Mice Model. *J. Control. Release* **2019**, *301*, 62–75. [\[CrossRef\]](#)
159. Cheng, C.Y.; Barro, L.; Tsai, S.T.; Feng, T.W.; Wu, X.Y.; Chao, C.W.; Yu, R.S.; Chin, T.Y.; Hsieh, M.F. Epigallocatechin-3-Gallate-Loaded Liposomes Favor Anti-Inflammation of Microglia Cells and Promote Neuroprotection. *Int. J. Mol. Sci.* **2021**, *22*, 3037. [\[CrossRef\]](#)
160. Abbasalipour, H.; Hajizadeh Moghaddam, A.; Ranjbar, M. Sumac and Gallic Acid-Loaded Nanophytosomes Ameliorate Hippocampal Oxidative Stress via Regulation of Nrf2/Keap1 Pathway in Autistic Rats. *J. Biochem. Mol. Toxicol.* **2022**, *36*, e23035. [\[CrossRef\]](#)
161. Mindell, J.A.; Meltzer, L.J.; Carskadon, M.A.; Chervin, R.D. Developmental Aspects of Sleep Hygiene: Findings from the 2004 National Sleep Foundation Sleep in America Poll. *Sleep Med.* **2009**, *10*, 771–779. [\[CrossRef\]](#)
162. Samanta, P.; Panigrahi, A.; Senapati, L.K.; Mishra, D.P.; Ravan, J.R.; Mishra, J. Maladaptive Behavior and Associated Factors among Young Children with Autism. *Indian J. Pediatr.* **2022**, *89*, 1134–1136. [\[CrossRef\]](#)

163. Evans, M.O.; Starley, B.; Galagan, J.C.; Yabes, J.M.; Evans, S.; Salama, J.J. Tea and Recurrent Clostridium Difficile Infection. *Gastroenterol. Res. Pract.* **2016**, *2016*, 4514687. [[CrossRef](#)]
164. Vossoughinia, H.; Salari, M.; Amirmajidi, E.M.; Saadatnia, H.; Abedini, S.; Shariati, A.; Shariati, M.; Khorashad, A.K. An Epidemiological Study of Gastroesophageal Reflux Disease and Related Risk Factors in Urban Population of Mashhad, Iran. *Iran. Red Crescent Med. J.* **2014**, *16*, e15832. [[CrossRef](#)]
165. Buie, T.; Campbell, D.B.; Fuchs, G.J.; Furuta, G.T.; Levy, J.; Van De Water, J.; Whitaker, A.H.; Atkins, D.; Bauman, M.L.; Beaudet, A.L.; et al. Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals with ASDs: A Consensus Report. *Pediatrics* **2010**, *125* (Suppl. S1), S1–S18. [[CrossRef](#)]
166. Kucera, O.; Mezera, V.; Moravcova, A.; Endlicher, R.; Lotkova, H.; Drahota, Z.; Cervinkova, Z. In Vitro Toxicity of Epigallocatechin Gallate in Rat Liver Mitochondria and Hepatocytes. *Oxid. Med. Cell. Longev.* **2015**, *2015*, 476180. [[CrossRef](#)]
167. Galati, G.; Lin, A.; Sultan, A.M.; O'Brien, P.J. Cellular and in Vivo Hepatotoxicity Caused by Green Tea Phenolic Acids and Catechins. *Free Radic. Biol. Med.* **2006**, *40*, 570–580. [[CrossRef](#)] [[PubMed](#)]
168. Mezera, V.; Kucera, O.; Moravcova, A.; Peterova, E.; Cervinkova, Z. The Effect of Epigallocatechin Gallate on Hepatocytes Isolated from Normal and Partially Hepatectomized Rats. *Can. J. Physiol. Pharmacol.* **2014**, *92*, 512–517. [[CrossRef](#)] [[PubMed](#)]
169. Chow, H.-H.S.; Cai, Y.; Hakim, I.A.; Crowell, J.A.; Shahi, F.; Brooks, C.A.; Dorr, R.T.; Hara, Y.; Alberts, D.S. Pharmacokinetics and Safety of Green Tea Polyphenols after Multiple-Dose Administration of Epigallocatechin Gallate and Polyphenon E in Healthy Individuals¹. *Clin. Cancer Res.* **2003**, *9*, 3312–3319. [[PubMed](#)]
170. Abe, S.K.; Inoue, M. Green Tea and Cancer and Cardiometabolic Diseases: A Review of the Current Epidemiological Evidence. *Eur. J. Clin. Nutr.* **2021**, *75*, 865–876. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.